28th Feb 2014 16:08
LONDON (Alliance News) - GlaxoSmithKline said Friday that it had submitted a new drug application to the US Food and Drug Administration for its severe aplastic anaemia treatment Promacta.
The treatment is used for patients with the condition who have had an insufficient response to immunosuppressive therapy.
Glaxo received breakthrough therapy designation for Promacta from the FDA February 3, 2013.
Shares in Glaxo were trading down 0.5% at 1,677.00 pence Friday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline